Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Nephron Pharmaceuticals history
Nephron Pharmaceuticals company history timeline
The FDA approved our first generic respiratory medication in 1997, and since then we've been committed to bringing safe, effective, and affordable medications to patients in need.
1997 Our first product approved
In 1997 Nephron Pharmaceutical Corporation (Nephron) received FDA approval for their first product albuterol inhalation solution, and then began helping patients gain access to affordable medication so they could breathe easier.
1998 Outgrowing our space
1999 Helping patients breathe easy Applied for Albuterol 0.5% Inhalation Solution ANDA
Opened in-house pharmacy for employees and their families Launched an educator program that employs over 860 local teachers Reached a total of 2000+ FTE and PTE employees Added 75,000 square feet of clean room manufacturing space Installed 4 new sterile BFS lines
2001 Swift growth Albuterol 0.5% Inhalation Solution ANDA approved Ipratropium Bromide 0.02% Inhalation Solution ANDA approved Expansion to 76,000 sq.ft.
2002 Getting the word out Lou Kennedy comes on board and begins to build marketing sales force
2003 Amplifying production Addition of 4 Weiler 640 BFS machines increased capacity to 58 million vials per month
2004 A breath of fresh air Albuterol 0.042% Inhalation Solution ANDA approved
2006 Keeping up with demand Nephron acquires its first pieces of Bosch high-speed packaging machinery
So in 2007, without a chemistry or engineering background, Kennedy jumped in, helping to propel unprecedented growth at the company.
2007 Improving efficiency and speed Ipratropium Bromide 0.5mg/ Albuterol Sulfate 3mg Inhalation Solution (DuoDose) ANDA approved Addition of a High Speed Single Vial Packaging Line - 35,000 vials per hour Advanced Processes and Quality Controls
2008 A year of continued growth
2009 Fighting for a level playing field Bill Kennedy hearing before the US House of Representatives on H.R. 1706: Protecting Consumer Access to Generic Drugs Act of 2009
2010 Expanding our reach
In 2011, Nephron Pharmaceutical Corporation announced its relocation for its new operations in Lexington County, SC. The $313 million facility was constructed in West Columbia and over 600 employees were hired.
2012 Relief, now OTC Sodium Chloride (hypertonic saline) 3% and 7% launched Nephron SC breaks ground Launch of our first OTC Medication Asthmanefrin
2014 Nephron moves to South Carolina Nephron headquarters relocated from Orlando, FL to West Columbia, SC Nephron was certified a woman-owned and woman-controlled business by NWBOC (National Women Business Owners Corporation)
2015 We're approved After 16 long months, Nephron finally receives full FDA approval
2016 Portable relief Budesonide 0.25mg and 0.5mg received ANDA approval National launch of the Pocket Neb
December 2017 – Nephron announced plans to expand its West Columbia facility, adding an additional 36,000 square feet of manufacturing space for its 503B Outsourcing Division (one of the fastest growing 503B facilities in America).
2017 Nephron is nationwide Nephron 503B Outsourcing Facility officially launched Became licensed in all 50 states
Six years later in 2017, the company announced an additional investment of $12.5 million expansion to add 36,000 square feet of manufacturing space.
2018 Expansion Released new opioid free alternatives Established free overnight delivery via UPS Reached a total of 900+ employees Launched a $12.5 million expansion
May 2019 - Nephron introduced the formation of their educator program, employing nearly 900 teachers to assist with company operations.
August 2019 - Clemson University announced its plan to partner with Nephron to develop a robotic solution for syringe filling automation.
March 2020 - In response to the COVID-19 pandemic the company increased production of its first-line protocol respiratory drug therapies needed for COVID-19 patients by 50% and launched a new manufacturing line to meet demands across the country.
In 2020, South Carolina had 21,818 open manufacturing jobs.
In 2020, Nephron expanded once more with an investment of $215.8 million bringing their total commitments to more than $500 million in SC.
February 2021– Nephron began providing COVID vaccines to employees and others across South Carolina.
Rate how well Nephron Pharmaceuticals lives up to its initial vision.
Nephron Pharmaceuticals jobs
Do you work at Nephron Pharmaceuticals?
Does Nephron Pharmaceuticals communicate its history to new hires?
Nephron Pharmaceuticals competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Allergan plc | 1948 | $7.2B | 11,400 | 41 |
| Boehringer Ingelheim | 1984 | $17.2B | 52,391 | 372 |
| Pharma Tech Industries | 1972 | $62.5M | 350 | - |
| LNK International | 1980 | $5.5M | 3,000 | 12 |
| NOW Foods | 1968 | $360.0M | 985 | 28 |
| The Ritedose | 1995 | $14.0M | 182 | 5 |
| Pharmasol | 1973 | $47.3M | 69 | - |
| Reed-Lane | 1959 | $18.8M | 125 | - |
| Hospira | 2004 | $4.5B | 19,000 | - |
| Xerimis | 2001 | $15.0M | 50 | - |
Nephron Pharmaceuticals history FAQs
Zippia gives an in-depth look into the details of Nephron Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Nephron Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Nephron Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Nephron Pharmaceuticals. The data presented on this page does not represent the view of Nephron Pharmaceuticals and its employees or that of Zippia.
Nephron Pharmaceuticals may also be known as or be related to Nephron Pharmaceuticals, Nephron Pharmaceuticals Corp, Nephron Pharmaceuticals Corp. and Nephron Pharmaceuticals Corporation.